Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
Novartis disclosed tumor reports in patients who received Zolgensma; a causal link remains unestablished.
TL;DR
- Novartis said it had received reports of tumors in patients previously treated with Zolgensma.
- STAT reported nine tumor reports, with two cases showing evidence that a connection to treatment may be possible.
- The company and patient organizations said health authorities were reviewing the safety information.
STAT reported that Novartis acknowledged seven previously unknown instances and had received nine tumor reports overall. The company said two cases showed evidence that tumors may be linked to treatment; this is a potential safety signal, not a confirmed causal finding. [1]
BioSpace also reported the nine cases and quoted Novartis saying it continually evaluates safety information and assesses reported cases. The article described the information as disclosed to clinicians and patient advocates. [2]
SMA UK relayed a Novartis statement shared with SMA Europe on November 5. The organization said the company had notified health authorities and would continue working with them on next steps. [3]
The reports do not establish incidence or causation, and the available accounts do not identify a common mechanism across the cases. Regulatory review and further clinical detail remain open. [1]
Why it matters
The disclosure is relevant to gene-therapy safety monitoring because Zolgensma is an established treatment and the reported events involve a serious outcome. The evidence remains preliminary, so regulatory assessment and case-level details will determine what the signal means.
Editor's note
Potential association only; do not infer causation or estimate risk from the case reports. No treatment guidance is offered.